SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01670396

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents

The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).

NCT01670396 Coronary Artery Disease
MeSH: Coronary Artery Disease
HPO: Coronary artery atherosclerosis


Primary Outcomes

Measure: In-stent restenosis

Time: 6-24months after stent implanting

Secondary Outcomes

Measure: target lesion revascularization (TLR)

Time: 6-24months after stent implanting

Measure: re-myocardial infarction

Time: 6-24months after stent implating

Time Perspective: Retrospective

Case Control


There is one SNP

SNPs


1 C825T

The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins. --- C825T ---



HPO Nodes


HPO:
Coronary artery atherosclerosis
Genes 48
LMNA LDLRAP1 LDLR ACTA2 CYP7A1 FBN1 APOE APOB ESR1 MAT2A ABCA1 KCNJ5 ABCG8 MYH11 ZNF687 TGFB2 LMNA LMNA ELN LMNA LIPC PPARG LMNA FOXE3 SERPIND1 SMAD4 TGFBR2 SMPD1 MFAP5 ABCA1 APOB LMNA LOX SMAD3 MYH11 MYH11 LOX LMNA PCSK9 ACTA2 ABCG8 ZMPSTE24 TGFB3 PRKG1 TGFBR1 MYLK CEP19 ABCG5